Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Oncotarget | 2015

Ovarian cancer represents the most lethal tumor type among malignancies of the female reproductive system. Overall survival rates remain low. In this study, we identify the serine protease inhibitor Kazal type 1 (SPINK1) as a potential therapeutic target for a subset of ovarian cancers. We show that SPINK1 drives ovarian cancer cell proliferation through activation of epidermal growth factor receptor (EGFR) signaling, and that SPINK1 promotes resistance to anoikis through a distinct mechanism involving protease inhibition. In analyses of ovarian tumor specimens from a Mayo Clinic cohort of 490 patients, we further find that SPINK1 immunostaining represents an independent prognostic factor for poor survival, with the strongest association in patients with nonserous histological tumor subtypes (endometrioid, clear cell, and mucinous). This study provides novel insight into the fundamental processes underlying ovarian cancer progression, and also suggests new avenues for development of molecularly targeted therapies.

Pubmed ID: 26437224 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R21 CA177865
  • Agency: NCI NIH HHS, United States
    Id: R21CA177865
  • Agency: NCI NIH HHS, United States
    Id: R01 CA122443
  • Agency: NCI NIH HHS, United States
    Id: P30 CA015083
  • Agency: NCI NIH HHS, United States
    Id: P30CA15083
  • Agency: NCI NIH HHS, United States
    Id: R01CA122443
  • Agency: NCI NIH HHS, United States
    Id: R01CA154387
  • Agency: NCI NIH HHS, United States
    Id: P50CA136393
  • Agency: NCI NIH HHS, United States
    Id: P50 CA136393
  • Agency: NCI NIH HHS, United States
    Id: R01 CA154387

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


University of Texas MD Anderson Cancer Center (tool)

RRID:SCR_004699

The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. VISION: We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science. We are Making Cancer History.

View all literature mentions

MP Biomedicals (tool)

RRID:SCR_013308

An Antibody supplier

View all literature mentions

Dako (tool)

RRID:SCR_013530

An Antibody supplier; Dako was purchased by Agilent in 2012 and several years later the websites began to reflect the Dako products as part of the Agilent catalog.

View all literature mentions

HEK293-FT (tool)

RRID:CVCL_6911

Cell line HEK293-FT is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

OVCAR-3 (tool)

RRID:CVCL_0465

Cell line OVCAR-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions